DR. REDDY'S BIO-SCIENCES LIMITED
Location
Telangana
Founded
2000-06-27
Website
Risk Signals
1 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, In Vitro and In Vivo Diagnostic Substances), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about DR. REDDY'S BIO-SCIENCES LIMITED
Live alerts from global media, monitored by Business Radar
2025-02-06 (stocktitan.net)
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
Henlius partners with Dr. Reddy's, receiving $33M upfront plus $131.6M in potential milestones for HLX15 daratumumab biosimilar rights across US and European markets.
Read more
2023-10-25 (inc42.com)
Dr. Reddy’s Marks Its Ecommerce Foray With The Launch Of Celevida Wellness
The new ecommerce marketplace lists both Celevida products and other third-party brands on its website, and will be focussed on Type 2 diabetic and pre-diabetic individuals.
Read more
2023-07-12 (itnews.asia)
Pharmaceutical firm Dr. Reddy's migrates SAP workload to AWS - Cloud - Digital Transformation -
Dr. Reddy's Laboratories Limited (Dr. Reddy's), a leading multinational pharmaceutical company based out of India, has selected Amazon Web Services (AWS) as cloud provider to accelerate the development of new healthcare applications, grow the digital platform, and enable healthcare providers to track the progress of patients better.
Read more
(indiatimes.com)
Cyberattack on Dr Reddy's Labs sharp reminder to strengthen digital infrastructure: Analysts - ET HealthWorld
Cyber Attack: According to a report by HSBC, damage control and restoration of operations are crucial. It said Dr. Reddy's is a front runner among peers in terms of investing for digital transformation initiatives as well as for new-age cyber securities technologies.
Read more